EFFICIENCY OF A PROTOCOL TO PREVENT DELAYED CHEMOTHERAPY-INDUCED EMESIS
CP-056
EVALUATION OF PHARMACEUTICAL INTERVENTIONS IN A GENERAL MEDICAL AND A GERIATRIC UNITS
CP-051
ESTABLISHMENT OF A CLINICAL PHARMACY DEPARTMENT AT THE UNIVERSITY MEDICAL CENTRE, LJUBLJANA
CP-050
ADHERENCE TO PROTEIN TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKAEMIA AND GASTROINTESTINAL STROMAL TUMOURS
CP-048
MULTIDISCIPLINARY MANAGEMENT AS A RESOURCE FOR METABOLIC DISEASES: COOPERATION BETWEEN CLINICIANS AND PHARMACISTS IN AN ITALIAN CENTRE FOR RARE DISEASES
CP-047
HOW TO RESPOND TO HIGH LEVELS OF SERUM POTASSIUM
CP-044
AUDIT OF THE PATIENT TREATMENT PROCESS IN AN ONCOLOGY OUTPATIENT CLINIC: FROM WELCOME TO THE ADMINISTRATION OF CHEMOTHERAPY
CP-041
EVALUATION OF THE USE OF USTEKINUMAB IN CLINICAL PRACTICE AND ITS ECONOMIC IMPACT
CP-037
THROMBOLYSIS PERFORMED WITHIN THREE HOURS FOLLOWING STROKE REDUCES DISABILITY AND COSTS: AN ECONOMIC MODEL TO ESTIMATE SAVINGS
CP-036
EVALUATION OF OUTPATIENT CLINIC LETTERS FOR MEDICATION ERRORS
CP-032
PREVALENCE OF COMORBIDITIES AND EFFECT ON ART ADHERENCE IN HIV-INFECTED PATIENTS
CP-031
CONCURRENT USE OF CO-TREATMENT WITH ANTIRETROVIRALS REDUCES ADHERENCE TO HIV MEDICINES
CP-029
EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE TREATMENT IN PATIENTS WITH METASTATIC PANCREATIC CANCER
CP-028
HEART FAILURE PATIENTS NEED HEART FAILURE TEAMS
CP-027
PROTOCOLISED USE OF PROTEASE INHIBITORS FOR HEPATITIS C IN A HEALTH CARE AREA: 18 MONTHS OF COST SAVINGS
